Overall relationship between active disease (DAS>2.4) after 3 months of induction DMARD therapy and response to GCs at 2 weeks (A) and also stratified for induction therapy arms (B)
| Active disease | |||
|---|---|---|---|
| Yes (n=42) | No (n=78) | ||
| A. | |||
| Response to GCs at 2 weeks | |||
| Good, no (%) | 6 (13) | 39 (87) | |
| Moderate, no (%) | 17 (39) | 27 (61) | |
| None, no (%) | 19 (61) | 12 (39) | |
| B. | |||
| GCs response at 2 weeks | |||
| A. MTX+SSZ+HCQ+GCs IM, no (%) | |||
| Good | 3 (17) | 15 (83) | |
| Moderate | 3 (21) | 11 (79) | |
| None | 5 (45) | 6 (55) | |
| B. MTX+SSZ+HCQ+GCs oral, no (%) | |||
| Good | 1 (6) | 16 (94) | |
| Moderate | 5 (42) | 7 (58) | |
| None | 4 (40) | 6 (60) | |
| C. MTX+GCs oral, no (%) | |||
| Good | 2 (20) | 8 (80) | |
| Moderate | 9 (50) | 9 (50) | |
| None | 10 (100) | 0 (0) | |
DAS, Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; GCs, glucocorticoids; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate, SSZ, sulfasalazine.